Amid a decline in COVID-19 vaccinations, shares for two of the top mRNA vaccine manufacturers have dropped considerably this year.
Pfizer’s shares are down about 40 percent, and Moderna’s shares are down 55 percent for this year, coming as both companies recently released guidance on revenue projections. Novavax, which makes a COVID-19 vaccine that doesn’t use mRNA technology, has seen its stock drop by 63 percent for the year.
